

13366 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

TABLE A.2.—UGDP DATA: CARDIOVASCULAR FAILURE RATES FOR EACH TREATMENT GROUP

Treatment group	Number of patients	Number of failures	Total time at risk, quarter-years	Failure rate (in thousands)
Both sexes:				
Placebo.....	205	10	5,033.6	2.0
Tolbutamide.....	204	26	4,922.2	5.3
Standard dose insulin.....	210	13	5,203.9	2.5
Variable dose insulin.....	204	12	5,098.1	2.4
Males:				
Placebo.....	63	7	1,389.2	5.2
Tolbutamide.....	63	11	1,491.5	7.4
Standard dose insulin.....	57	5	1,340.0	3.7
Variable dose insulin.....	46	2	1,137.5	1.8
Women:				
Placebo.....	142	3	3,644.4	.8
Tolbutamide.....	141	15	3,430.7	4.4
Standard insulin dose.....	153	8	3,863.8	2.1
Variable dose insulin.....	158	10	3,960.6	2.5

TABLE A.4.—UGDP DATA: CARDIOVASCULAR FAILURE RATES FOR EACH TREATMENT GROUP BY AGE, AND SEX

Treatment Group	Number of patients	Number of failures	Total time at risk, quarter-years	Failure rate (in thousands)
Males:				
≤53 yr old:				
Placebo.....	28	1	664.6	1.5
Tolbutamide.....	26	5	656.6	7.6
Standard dose insulin.....	28	0	722.5	0
Variable dose insulin.....	21	1	521.7	1.9
>53 yr old:				
Placebo.....	35	6	724.5	8.3
Tolbutamide.....	37	6	834.9	7.2
Standard dose insulin.....	29	5	617.6	8.1
Variable dose insulin.....	25	1	615.8	1.6
≤53 yr old:				
Placebo.....	85	1	2,187.8	.5
Tolbutamide.....	71	1	1,793.8	.6
Standard dose insulin.....	79	1	2,048.6	.5
Variable dose insulin.....	82	1	2,118.9	.5
>53 yr old:				
Placebo.....	58	2	1,456.6	1.4
Tolbutamide.....	70	14	1,636.9	8.6
Standard dose insulin.....	74	7	1,815.2	3.9
Variable dose insulin.....	76	9	1,841.7	4.9